article thumbnail

AI-discovered ALS drug trial uses unique remote monitoring

Drug Discovery World

” The post AI-discovered ALS drug trial uses unique remote monitoring appeared first on Drug Discovery World (DDW). “We are tremendously excited by the potentially transformative power of our CONVERGE platform in redefining the landscape and expediting the journey from lab bench to patients and improving lives worldwide.”

article thumbnail

Patients achieve 19% weight loss in obesity drug trial

Drug Discovery World

The post Patients achieve 19% weight loss in obesity drug trial appeared first on Drug Discovery World (DDW). After 46 weeks of treatment, up to 40% of people who reached the highest two doses of survodutide achieved a weight loss of at least 20%, versus 0% with placebo (actual treatment analysis).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Scleroderma drug trial shows up to 60% improvement

Drug Discovery World

The post Scleroderma drug trial shows up to 60% improvement appeared first on Drug Discovery World (DDW). It is important to advance safe and effective treatments through clinical development, given the limited therapeutic options for scleroderma patients.

article thumbnail

Phase III pulmonary fibrosis drug trial fails

Drug Discovery World

“The REBUILD study did not match the outcomes we saw in the exploratory Phase II study in this patient population; however, the overall outcome of this pivotal validation study is conclusive and we do not see a path forward for continuing the REBUILD trial,” said Peter Fernandes, Bellerophon’s Chief Executive Officer.

article thumbnail

First patient dosed in ulcerative colitis drug trial

Drug Discovery World

The post First patient dosed in ulcerative colitis drug trial appeared first on Drug Discovery World (DDW). This is measured by changes in laboratory values including C-reactive protein and faecal calprotectin, and changes in validated clinical and endoscopic scoring systems.

article thumbnail

Alnylam change to heart drug trial sparks doubts, sinking shares

BioPharma Drive: Drug Pricing

Analysts pressed Alnylam executives on the reasons for the changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future.

article thumbnail

EyePoint sees stock surge on AMD drug trial data

BioPharma Drive: Drug Pricing

The biotech said Phase 2 study results showed its experimental medicine for age-related macular degeneration was "non-inferior" to Regeneron's Eylea.